Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Elton Jalis Herman, Carla Debernardi, Khadija Sana Hafeez, Sara Devito, Tze Yin Lim, Alessia Russo, Alessandra Allione, Elisabete Weiderpass, Antonio Agudo, Marta La Vecchia, Irma Dianzani, Natalia Cabrera Castro, Vittorio Simeon, Rosario Tumino, Laia Peruchet-Noray, Ana Jiménez-Zabala, Paolo Vineis, Elisabetta Casalone, Giuseppe Matullo
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1038/s41467-018-05467-z
10.1038/s41467-018-05467-z
10.1016/j.envint.2023.108165
10.1016/j.envint.2023.108165
10.1016/s0140-6736(20)32714-8
10.1016/s0140-6736(20)32714-8
10.1016/j.annonc.2022.01.074
10.1016/j.annonc.2022.01.074
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
10.1016/j.annonc.2024.12.014 · 2025
10.1038/s41416-022-01979-0
10.1038/s41416-022-01979-0
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations
10.1016/j.jtho.2022.03.014 · 2022
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome
10.1038/s41431-023-01448-z · 2023
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas
10.1016/j.jtho.2019.12.111 · 2020
10.1016/j.lungcan.2023.03.008
10.1016/j.lungcan.2023.03.008
10.1016/j.canlet.2016.05.011
10.1016/j.canlet.2016.05.011
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma
10.1016/j.canlet.2017.06.028 · 2017
Treatment of Pleural Mesothelioma: ASCO Guideline Update
10.1200/jco-24-02425 · 2025
Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment
10.1016/j.ejca.2021.12.023 · 2022
10.1093/carcin/bgu227
10.1093/carcin/bgu227
10.1073/pnas.1821510116
10.1073/pnas.1821510116
10.1200/jco.2018.79.0352
10.1200/jco.2018.79.0352
BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities
10.1038/s41388-025-03672-x · 2026
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
2024
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
10.1016/s1470-2045(22)00277-7 · 2022
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma
10.1038/s41416-024-02661-3 · 2024
10.1038/s41588-018–0183-z
10.1038/s41588-018–0183-z
10.1038/s41568-023-00599-x
10.1038/s41568-023-00599-x
Individuals who deviate from polygenic expectation are enriched for damaging variants in genes linked to rare disease
10.1016/j.ajhg.2026.05.013 · 2026
10.1038/s41467-026-72185-2
10.1038/s41467-026-72185-2
10.1016/j.ejca.2010.07.025
10.1016/j.ejca.2010.07.025
Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort
10.1002/ijc.34339 · 2023
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects
10.1016/j.jtho.2018.10.163 · 2019
10.3390/cancers15010125
10.3390/cancers15010125
10.1002/ijc.70316
10.1002/ijc.70316
10.1007/s10238-026-02058-x
10.1007/s10238-026-02058-x
10.3390/jpm14101025
10.3390/jpm14101025
10.1158/1055-9965.epi-13-0119-t
10.1158/1055-9965.epi-13-0119-t
10.1038/gim.2015.30
10.1038/gim.2015.30
10.1111/cge.14516
10.1111/cge.14516
10.1016/j.ajhg.2012.06.007
10.1016/j.ajhg.2012.06.007
10.1093/biostatistics/kxv033
10.1093/biostatistics/kxv033
10.1093/bioinformatics/btw079
10.1093/bioinformatics/btw079
10.1371/journal.pone.0061253
10.1371/journal.pone.0061253
Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes
10.1001/jamaophthalmol.2016.0903 · 2016
10.1186/s12967-019-2058-1
10.1186/s12967-019-2058-1 · doi-reference
10.3389/fimmu.2024.1365975
10.3389/fimmu.2024.1365975 · doi-reference
10.1016/j.molcel.2021.04.002
10.1016/j.molcel.2021.04.002 · doi-reference
Wnt/beta-catenin signaling in cancers and targeted therapies
10.1038/s41392-021-00701-5 · doi-reference
10.3389/fgene.2014.00441
10.3389/fgene.2014.00441 · doi-reference
10.1038/s41525-019-0087-6
10.1038/s41525-019-0087-6 · doi-reference
Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors
10.1093/hmg/ddab138 · doi-reference
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma
10.1001/jamanetworkopen.2023.27351 · doi-reference
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
10.1200/jco.2018.78.5204 · doi-reference
10.1038/s41431-024-01611-0
10.1038/s41431-024-01611-0 · doi-reference
10.1002/jha2.557
10.1002/jha2.557 · doi-reference
10.1136/jmedgenet-2019-106657
10.1136/jmedgenet-2019-106657 · doi-reference
10.1073/pnas.2019652117
10.1073/pnas.2019652117 · doi-reference